Published date: 18 November 2021

Last edited date: 15 November 2022

This notice was replaced on 15 November 2022

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 15 November 2022)

Awarded contract - This means that the contract has been awarded to a supplier.


Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

SW1H 0EU

Value of contract

£1

Procurement reference

CF-0346000D0O000000rwimUAA4

Published date

18 November 2021

Closing date

10 August 2021

Closing time

11pm

Contract start date

11 August 2021

Contract end date

31 March 2022

Contract type

Supply contract

Procedure type

Negotiated procedure without prior publication (above threshold)

The opportunity was not advertised, because for example only one supplier is capable of delivering the requirement, or due to extreme urgency brought about by unforeseen events.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

The evolution of the UK's pandemic response has highlighted the critical importance and economic value of a multi-layered and comprehensive approach to COVID-19.
The need for antibodies and other therapeutics has always been under consideration, the mutation of the virus and the risk this poses on antibody and vaccine efficacy has only recently been properly identified and still requires further academic studies.
These unforeseen circumstances mean there is now a critical, urgent need to procure and deploy a new class of mAbs, that can neutralise any COVID-19 variant. These neutralising mAbs provide protection to a cohort of the population who, for medical reasons, cannot mount an appropriate immune response to vaccination or, for whatever reason, do not get vaccinated and are also at higher risk of hospitalisation or death.
This agreement is for the procurement of 100,008 units of Sotrovimab (VIR-7831).

More information

Previous notice about this procurement

VIR-7831 Supply Agreement for Pandemic Purposes

  • Awarded contract
  • Published 13 September 2021

Attachments

Award information

Awarded date

11 August 2021

Contract start date

11 August 2021

Contract end date

31 March 2022

Total value of contract

£1

This contract was awarded to 1 supplier.

GlaxoSmithKline UK Limited

Address

GSK House, 980 Great West Road, Middlesex TW8 9GS

Reference

None

Supplier is SME?

No

Supplier is VCSE?

No

About the buyer

Contact name

Amy Watkins

Address

39 Victoria Street
London
SW1H 0EU
GB

Email

TherapeuticsTaskforce@dhsc.gov.uk